Compare HBAN & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBAN | RMD |
|---|---|---|
| Founded | 1866 | 1989 |
| Country | United States | United States |
| Employees | 24641 | 10600 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3B | 29.4B |
| IPO Year | N/A | N/A |
| Metric | HBAN | RMD |
|---|---|---|
| Price | $15.89 | $207.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $19.73 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 18.2M | 1.3M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.80% | 1.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.83 | $10.60 |
| Revenue Next Year | $9.27 | $7.41 |
| P/E Ratio | ★ $12.87 | $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.89 | $198.61 |
| 52 Week High | $19.44 | $293.81 |
| Indicator | HBAN | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 43.72 |
| Support Level | $15.07 | $198.63 |
| Resistance Level | $16.15 | $260.21 |
| Average True Range (ATR) | 0.33 | 4.85 |
| MACD | -0.02 | 1.26 |
| Stochastic Oscillator | 44.89 | 62.06 |
Huntington is a regional US bank with over $285 billion in assets. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.